Evidence map›Paper›PMID 27747012›Full record

ArticleJournal of thoracic disease2016

Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

Priska Leisibach, Didier Schneiter, Alex Soltermann, Yoshi Yamada, Walter Weder, Wolfgang Jungraithmayr

Open access · hybridAbstract read
In one paragraph

Article in Journal of thoracic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Thymic Epithelial Tumors: An Evolving Field.Life (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Priska LeisibachDivision of Thoracic Surgery, University Hospital Zurich, Zurich 8091, Switzerland.
Didier SchneiterDivision of Thoracic Surgery, University Hospital Zurich, Zurich 8091, Switzerland.
Alex SoltermannDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich 8091, Switzerland.
Yoshi YamadaDivision of Thoracic Surgery, University Hospital Zurich, Zurich 8091, Switzerland.
Walter WederDivision of Thoracic Surgery, University Hospital Zurich, Zurich 8091, Switzerland.
Wolfgang JungraithmayrDivision of Thoracic Surgery, University Hospital Zurich, Zurich 8091, Switzerland.
University Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThymic epithelial tumors (TET) are rare neoplasms with inconsistent treatment strategies. When researching for molecular pathways to find new therapies, the correlation between specific molecular markers and outcome has only rarely been investigated. The aim of this study was to investigate the correlation between survival, metastatic potential and invasiveness of aggressive subtypes of TET and immunohistochemical markers.

methodsOverall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and metastasis-free survival (MFS) of patients with WHO type B2/B3 mixed type thymoma (MT), thymoma type B3 (B3) and thymic carcinoma (TC), undergoing surgery [1998-2013] were determined. Tumor specimens were stained using a tissue microarray (TMA) (CD117, CD5, p63, p40, p21, p27, p53, Bcl-2, Ki67, podoplanin, synaptophysin, PTEN and Pax8). Invasive behavior of primary tumors and the presence of extrathoracic metastases were assessed.

resultsWe found in 23 patients included into this study (four MT, ten B3, nine TC) that (I) p21 expression in the cytoplasm significantly correlated with a decrease of OS (P=0.016), PFS (P=0.034) and MFS (P=0.005); (II) MFS was significantly shorter when the combination of p21-low p27-low p53-high was present (P=0.029); and (III) nuclear p27 (P=0.042), Ki-67 (P=0.024) and podoplanin (P=0.05) expression correlated with the presence of extrathoracic metastases.

conclusionsThe main finding of this study is that cytoplasmic p21 expression negatively influences the outcome of malignant TETs and correlates with metastatic activity. Additionally, selected immunohistochemical markers correlate with the distant metastatic potential of TETs. These results may contribute to the stratification of diagnosis and improvement of treatment strategies for thymic malignancies.

Indexed as

immunohistochemistrymetastasesthymic carcinoma (TC)Thymoma

Identifiers

PMID27747012
PMCPMC5059354
OpenAlexW2516995909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.